Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.

This is the first open label study to use apremilast as a treatment modality for discoid lupus. Our observations indicate that apremilast may constitute a safe and effective therapeutic option for DLE.